Targeting mTOR with curcumin: therapeutic implications for complex diseases

Basit Öğe Kaydı
dc.authoridRazavi, Seyed Mehrad/0000-0002-7877-7958
dc.contributor.authorKhayatan, Danial
dc.contributor.authorRazavi, Seyed Mehrad
dc.contributor.authorArab, Zahra Najafi
dc.contributor.authorNasoori, Hadis
dc.contributor.authorFouladi, Abtin
dc.contributor.authorPasha, Aytak Vahdat Khajeh
dc.contributor.authorButler, Alexandra E.
dc.date.accessioned2025-05-29T02:58:05Z
dc.date.available2025-05-29T02:58:05Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractThe mammalian target of rapamycin (mTOR) is a crucial enzyme in regulating multiple signaling pathways in the body, including autophagy, proliferation and apoptosis. Disruption of these mTOR signaling pathways can lead to an array of abnormalities and trigger disease processes, examples being neurodegenerative conditions, cancer, obesity and diabetes. Under conditions of oxidative stress, mTOR can regulate apoptosis and autophagy, with tissue repair being favored under such circumstances. Moreover, the correlation between mTOR and other signaling pathways could play a pivotal role in the pathophysiology of numerous disorders. mTOR has a tight connection with NF-kappa B, Akt, PI3K, MAPK, GSK-3 beta, Nrf2/HO-1, JAK/STAT, CREB/BDNF, and ERK1/2 pathways, which together could play significant roles in the regulation of inflammation, apoptosis, cell survival, and oxidative stress in different body organs. Research suggests that inhibiting mTOR could be beneficial in treating metabolic, neurological and cardiovascular conditions, as well as potentially extending life expectancy. Therefore, identifying new chemicals and agents that can modulate the mTOR signaling pathway holds promise for treating and preventing these disorders. Curcumin is one such agent that has demonstrated regulatory effects on the mTOR pathway, making it an exciting alternative for reducing complications associated with complex diseases by targeting mTOR. This review aims to examine the potential of curcumin in modulating the mTOR signaling pathway and its therapeutic implications.
dc.identifier.doi10.1007/s10787-025-01643-y
dc.identifier.endpage1616
dc.identifier.issn0925-4692
dc.identifier.issn1568-5608
dc.identifier.issue4
dc.identifier.pmid39955697
dc.identifier.scopus2-s2.0-85218201212
dc.identifier.scopusqualityQ1
dc.identifier.startpage1583
dc.identifier.urihttps://doi.org/10.1007/s10787-025-01643-y
dc.identifier.urihttps://hdl.handle.net/20.500.12428/30270
dc.identifier.volume33
dc.identifier.wosWOS:001422012900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Basel Ag
dc.relation.ispartofInflammopharmacology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250529
dc.subjectCurcuma longa
dc.subjectMammalian target of rapamycin (mTOR)
dc.subjectInflammatory Signaling Pathways
dc.titleTargeting mTOR with curcumin: therapeutic implications for complex diseases
dc.typeReview

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu